The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)—A two-cohort phase II study.
 
Clemens-Martin Wendtner
Honoraria - Abbvie; Gilead Sciences; MorphoSys
Consulting or Advisory Role - Abbvie; Gilead Sciences; MorphoSys
Research Funding - Abbvie; Gilead Sciences; MorphoSys
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; MorphoSys
 
John C. Byrd
Research Funding - Acerta Pharma; Genentech; Pharmacyclics
 
Robin Foà
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; Roche; Sandoz
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; Roche; Sandoz
Speakers' Bureau - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; Roche; Sandoz
Expert Testimony - GlaxoSmithKline; Takeda
 
Richard Greil
Honoraria - Celgene; Roche
Consulting or Advisory Role - Celgene; Roche
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Roche
 
Peter Hillmen
No Relationships to Disclose
 
Ulrich Jäger
No Relationships to Disclose
 
Wojciech Jurczak
Consulting or Advisory Role - MorphoSys; Sandoz-Novartis
Research Funding - Abbvie; AstraZeneca; Bayer; Celltrion; Gilead Sciences; Janssen; Merck; MorphoSys; Roche; Sandoz-Novartis; Takeda
 
Peter Kelemen
Employment - MorphoSys
Patents, Royalties, Other Intellectual Property - MorphoSys
 
Kamel Laribi
Honoraria - Amgen; Novartis; Takeda
Research Funding - Amgen; Hospira; Janssen-Cilag; Mundipharma; Novartis; Roche; Takeda; Teva
 
Talha Munir
Honoraria - Abbvie; Gilead Sciences; Janssen; Roche
Consulting or Advisory Role - MorphoSys
 
Johannes Schetelig
Consulting or Advisory Role - Janssen; Sanofi
Research Funding - Abbvie (Inst); Novartis (Inst)
 
Philipp B. Staber
Consulting or Advisory Role - Abbvie; Celgene; CTI; Gilead Sciences; Janssen; Karyopharm Therapeutics; MorphoSys; Roche
Research Funding - Takeda
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Janssen; Roche; Takeda
 
Stephan Stilgenbauer
No Relationships to Disclose
 
Jennifer Ann Woyach
Consulting or Advisory Role - Janssen
Research Funding - Acerta Pharma (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst)